CytRx logo

CYTR - CytRx Share Price

$0.619 -0.0  -0.2%

Last Trade - 7:58pm

Micro Cap
Market Cap £17.8m
Enterprise Value £6.31m
Revenue £n/a
Position in Universe 5220th / 6393
Unlock CYTR Revenue
Relative Strength (%)
1m +2.43%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -26.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.10 0.10 0.20 0.10 0.25 0.000 -100.0%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, CytRx Corporation revenues was not reported. Net loss before extraordinary items decreased 18% to $2.5M. Lower net loss reflects General and administrative decrease of 60% to $1.1M (expense), Employee stock and stock option expense decrease of 80% to $87K (expense), Rental Expense decrease of 42% to $80K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


CYTR Revenue Unlock CYTR Revenue

Net Income

CYTR Net Income Unlock CYTR Revenue

Normalised EPS

CYTR Normalised EPS Unlock CYTR Revenue

PE Ratio Range

CYTR PE Ratio Range Unlock CYTR Revenue

Dividend Yield Range

CYTR Dividend Yield Range Unlock CYTR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CYTR EPS Forecasts Unlock CYTR Revenue
Profile Summary

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated February 28, 1985
Public Since November 10, 1986
No. of Shareholders: 257
No. of Employees: 4
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange OTC Markets Group
Shares in Issue 36,480,038
Free Float (0.0%)
Eligible for
CYTR Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CYTR
Upcoming Events for CYTR
Frequently Asked Questions for CytRx
What is the CytRx share price?

As of 7:58pm, shares in CytRx are trading at $0.619, giving the company a market capitalisation of £17.8m. This share price information is delayed by 15 minutes.

How has the CytRx share price performed this year?

Shares in CytRx are currently trading at $0.619 and the price has moved by 0.103k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the CytRx price has moved by 90.8% over the past year.

What are the analyst and broker recommendations for CytRx?

Of the analysts with advisory recommendations for CytRx, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for CytRx is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will CytRx next release its financial results?

CytRx is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the CytRx dividend yield?

CytRx does not currently pay a dividend.

Does CytRx pay a dividend?

CytRx does not currently pay a dividend.

When does CytRx next pay dividends?

CytRx does not currently pay a dividend.

How do I buy CytRx shares?

To buy shares in CytRx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of CytRx?

Shares in CytRx are currently trading at $0.619, giving the company a market capitalisation of £17.8m.

Where are CytRx shares listed? Where are CytRx shares listed?

Here are the trading details for CytRx:

Country of listing: United States
Exchange: OTC
Ticker Symbol: CYTR
What kind of share is CytRx?

Based on an overall assessment of its quality, value and momentum, CytRx is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a CytRx share price forecast 2020?

Shares in CytRx are currently priced at $0.619. At that level they are trading at 0.626% discount to the analyst consensus target price of 0.00.

Analysts covering CytRx currently have a consensus Earnings Per Share (EPS) forecast of -0.3 for the next financial year.

How can I tell whether the CytRx share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CytRx. Over the past six months, the relative strength of its shares against the market has been 24.27%. At the current price of $0.619, shares in CytRx are trading at 9.43% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the CytRx PE Ratio?

We were not able to find PE ratio data for CytRx.

Who are the key directors of CytRx?

CytRx's management team is headed by:

Louis Ignarro - IND
Steven Kriegsman - CHM
John Caloz - CFO
Earl Brien - DRC
Joel Caldwell - DRC
Who are the major shareholders of CytRx?

Here are the top five shareholders of CytRx based on the size of their shareholding:

Kriegsman (Steven A) Individual Investor
Percentage owned: 7.43% (2.71m shares)
ImmunityBio Inc Corporation
Percentage owned: 5.4% (1.97m shares)
Ignarro (Louis J) Individual Investor
Percentage owned: 1.18% (431k shares)
Brien (Earl W. M.D.) Individual Investor
Percentage owned: 0.44% (160k shares)
Colonial Trust Advisors, Inc. Investment Advisor
Percentage owned: 0.03% (11.3k shares)
Similar to CYTR
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.